Similar Search Results

The Objectives of the FDA's Office of Generic Drugs

Morton, Fiona Scott - 1997

I use variation in approval time for generic drugs to shed light on the objectives of the federal agency in charge of granting entry permission for these drugs (FDA). Applications belonging to firms later found to have engaged in fraud or corruption were approved nine months faster on average,...

Persistent link: https://www.econbiz.de/10012472670

"Generic Entry and the Pricing of Pharmaceuticals"

Frank, Richard G. - 1995

During the 1980s the share of prescriptions sold by retail pharmacies that was accounted for by generic products roughly doubled. The price response to generic entry of brand-name products has been a source of controversy. In this paper we estimate models of price responses to generic entry in...

Persistent link: https://www.econbiz.de/10012473564

Generics and New Goods in Pharmaceutical Price Indexes

Griliches, Zvi - 1993

We examine the issue of new goods and price indexes for the important and tractable case of generic and branded drugs. By treating generics as entirely distinct goods and "linking them in" to indexes with fixed weights, the standard price indexes fail to reflect the substantial welfare gains to...

Persistent link: https://www.econbiz.de/10012474690

Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets

Conti, Rena M. - 2019

We establish four facts concerning competition among U.S. generic drug suppliers, using IQVIA's National Sales Perspective™ 2004Q4 - 2016Q3 data. We define a unique product market ("molform"), consisting of the combination of a molecule active ingredient and a route of administration...

Persistent link: https://www.econbiz.de/10012480138

The New Prescription Drug Paradox : Pipeline Pressure and Rising Prices

Ellyson, Alice M. - 2018

Economic literature has extensively studied how prices for incumbent pharmaceutical drugs respond to generic competition after entry. However, less attention has been paid to pricing behavior in anticipation of brand-to-brand competition. We contribute to this gap in the literature by both...

Persistent link: https://www.econbiz.de/10012453327

Markups and Fixed Costs in Generic and Off-Patent Pharmaceutical Markets

Ganapati, Sharat; McKibbin, Rebecca - National Bureau of Economic Research - 2021

There is wide dispersion in pharmaceutical prices across countries with comparable quality standards. Under monopoly, off-patent and generic drug prices are at least four times higher in the United States than in comparable English-speaking high income countries. With five or more competitors,...

Persistent link: https://www.econbiz.de/10012629426

Most-Favored Entry Clauses in Drug Patent Litigation Settlements as a Potential Reverse Payment

Drake, Keith M.; McGuire, Thomas G. - National Bureau of Economic Research - 2022

Settlements of drug patent disputes that involve a potential payment from the brand to the generic signal a possible collusive profit split with a threat to competition, and have undergone intensive scrutiny in the literature on law and economics. A common feature of these brand-generic...

Persistent link: https://www.econbiz.de/10012938770

Generic Scrip Share and the Price of Brand-Name Drugs : The Role of the Consumer

Rizzo, John A. - 2005

Generic drug utilization has risen dramatically, from 19% of scrips in 1984 to 47% in 2001, thus bringing significant direct dollar savings. Generic drug use may also yield indirect savings if it lowers the average price of those brand-name drugs that are still purchased. Prior work indicates -...

Persistent link: https://www.econbiz.de/10012467248

"Napsterizing" Pharmaceuticals : Access, Innovation, and Consumer Welfare

Hughes, James W. - 2002

We analyze the effects on consumers of an extreme policy experiment -- Napsterizing' pharmaceuticals -- whereby all … associated with greater access to the current stock of pharmaceuticals, future consumers will be harmed by reducing the flow of … new pharmaceuticals to the market. Our estimates of the consumer surpluses at stake are based on the stylized facts …

Persistent link: https://www.econbiz.de/10012469480

Pharmaceutical Use Following Generic Entry : Paying Less and Buying Less

Huckfeldt, Peter J. - 2011

We study the effects of generic entry on prices and utilization using both event study models that exploit the differential timing of generic entry across drug molecules and cast studies. Our analysis examines drugs treating hypertension, high blood pressure, type 2 diabetes, and depression...

Persistent link: https://www.econbiz.de/10012461612

1
2
3
4
5
6
7
8
9
10
Next
Last